An interventional study of Oxytocin in Postpartum Hemorrhage, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing oxytocin in Postpartum Hemorrhage — 8 open to participants now, 9 under way, 1 of them phase 3. Oxytocin · Postpartum Hemorrhage.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, this one is the 45th largest by planned enrollment, is one of 4 that started in 2022, is one of 37 with no phase, and was the 51st registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 64 studies testing oxytocin in Postpartum Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
Mansoura University · Sites in Saudi Arabia
Ages 18–45 · Women only
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–40 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
Khyber Girls Medical College · Sites in Pakistan
Ages 18–40 · Women only
Assiut University
Ages 18–45 · Women only
By country, each count listing its studies:
Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 8 · Phase 4 9
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 108 across the 64 interventional studies. Of the 42 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 64 have an industry lead sponsor. The 10 most frequent:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital: 5 open now, 6 under way, none of them phase 3. Of 28 finished, 0 (0%) have results posted.
Among the 34 studies in Postpartum Hemorrhage by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 16th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 32 with no phase, and was the 27th registered.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s Postpartum Hemorrhage studies by the year they started, since 2007.
4 of the studies testing oxytocin in Postpartum Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05290129Samuel Lunenfeld Research Institute, Mount Sinai HospitalOxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study | 2026-12 |
| NCT06333340Samuel Lunenfeld Research Institute, Mount Sinai HospitalComparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery | 2026-12 |
| NCT07784478Khyber Girls Medical CollegeEffect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia | 2027-04-01 |
| NCT06930391Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies testing oxytocin in Postpartum Hemorrhage, from their registry updates:
Among Samuel Lunenfeld Research Institute, Mount Sinai Hospital’s 34 in Postpartum Hemorrhage:
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient.
The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.
This study will be conducted as a prospective, double blinded clinical trial (patient, anesthesiologist and obstetrician blinded to the oxytocin dose), in an up-down sequential allocation fashion. The objective of the study is to determine the minimum effective dose of oxytocin infusion required to produce appropriate uterine contraction during and after cesarean delivery under neuraxial anesthesia in laboring women. For the purpose of this study, the minimum effective dose is defined to be that at which adequate response occurs in 90% of patients, i.e. ED90.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The maintenance infusion rate of oxytocin will be 4 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 6 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 10 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 14 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 18 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 22 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 26 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 30 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 34 IU/h.
Drug: Oxytocin
The maintenance infusion rate of oxytocin will be 36 IU/h.
Drug: Oxytocin
Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
Also known as: Pitocin
Uterine tone up to discharge from the post anesthetic care unit (PACU): questionnaire
Uterine tone will be evaluated as satisfactory or unsatisfactory by the obstetrician throughout the surgery, starting at 5 minutes after the oxytocin infusion. It will also be measured at 10 minutes following the oxytocin infusion and every 10 minutes following that for the duration of the surgery. Unsatisfactory uterine tone at any time until discharge from the PACU will be considered a failure of the maintenance infusion.
Time frame: 2 hours
Calculated blood loss
Estimated blood loss will be calculated using the difference in hematocrit values prior to surgery and 24 hours post surgery, using the following formula: Calculated blood loss (mL) = EBV ((Pre-op Htc-Post-op Htc)/pre-op Htc) EBV (estimated blood volume) in ml: patient's weight in kg x 85.
Time frame: 24 hours
Need for blood transfusion
Blood product administered.
Time frame: 24 hours
Episodes of bleeding postpartum
Number of episodes of bleeding postpartum up to 24 hours post delivery.
Time frame: 24 hours
Intraoperative requirement for additional uterotonic medication
A request made by the obstetrician performing the cesarean delivery for additional uterotonic medication, due to bleeding or poor uterine tone.
Time frame: 1 hour
Requirement for additional uterotonic medication in the PACU
Any uterotonic medication administered while the patient is in PACU
Time frame: 2 hours
Requirement for additional uterotonic medication from discharge from the PACU until 24 hours postpartum.
Any uterotonic medication administered after the patient is discharged from PACU until 24 hours postpartum.
Time frame: 24 hours
Hypotension: systolic blood pressure less than 80% of baseline
Systolic blood pressure \< 80% of baseline, from drug administration until end of surgery
Time frame: 2 hours
Hypertension: systolic blood pressure greater than 120% of baseline
Systolic blood pressure \> 120% of baseline, from drug administration until end of surgery
Time frame: 2 hours
Tachycardia: heart rate greater than 130% of baseline
Heart rate \> 130% of baseline, from drug administration until end of surgery
Time frame: 2 hours
Bradycardia: heart rate less than 70% of baseline
Heart rate \< 70% of baseline or a heart rate \< 50bpm, from drug administration until end of surgery
Time frame: 2 hours
Presence of ventricular tachycardia: ECG
Presence of ventricular tachycardia as recorded by ECG, from drug administration until end of surgery
Time frame: 2 hours
Presence of atrial fibrillation: ECG
Presence of atrial fibrillation as recorded by ECG, from drug administration until end of surgery
Time frame: 2 hours
Presence of atrial flutter: ECG
Presence of atrial flutter as recorded by ECG, from drug administration until end of surgery
Time frame: 2 hours
Presence of nausea: questionnaire
The presence of nausea and number of episodes, from drug administration until end of surgery, as reported by the patient
Time frame: 2 hours
Presence of vomiting: questionnaire
The presence of vomiting and number of episodes, from drug administration until end of surgery
Time frame: 2 hours
Presence of chest pain: questionnaire
Any presence of chest pain, from drug administration until end of surgery, as reported by the patient
Time frame: 2 hours
Presence of shortness of breath: questionnaire
Any presence of shortness of breath, from drug administration until end of surgery, as reported by the patient
Time frame: 2 hours
Presence of headache: questionnaire
Any presence of headache, from drug administration until end of surgery, as reported by the patient
Time frame: 2 hours
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 52 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxytocin
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →